Serum M30 levels are associated with survival in advanced gastric carcinoma patients

Yaman E., Coskun U., Sancak B., Buyukberber S., Ozturk B., Benekli M.

INTERNATIONAL IMMUNOPHARMACOLOGY, cilt.10, sa.7, ss.719-722, 2010 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 10 Sayı: 7
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1016/j.intimp.2010.03.013
  • Dergi Adı: INTERNATIONAL IMMUNOPHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.719-722
  • Anahtar Kelimeler: Gastric cancer, Serum M65 levels, Serum M30 level, CASPASE-CLEAVED CYTOKERATIN-18, CELL-DEATH, CIRCULATING BIOMARKERS, CANCER PATIENTS, APOPTOSIS, TUMOR, CHEMOTHERAPY, FRAGMENTS, PRODUCT, PREDICT
  • Gazi Üniversitesi Adresli: Evet

Özet

Background: Cytokeratin 18 (CK-18) is a cytoskeleton protein of epithelial cells which are released into the circulation during necrotic or apoptotic cell death. M30 detects caspase-cleaved neo-epitope of CK-18; whereas M 65 measures whole length intact protein. We aimed to evaluate the prognostic significance of serum M65 and M30 levels in patients with gastric carcinoma.